Linked Life Data

7745515

Source:http://linkedlifedata.com/resource/pubmed/id/7745515

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5 Pt 2
pubmed:dateCreated
1995-6-13
pubmed:abstractText
This study determined outcomes at 12-months adjusted age of 957 infants weighing more than 1250 gm at birth who were subjects in a randomized, double-blind, controlled trial of synthetic surfactant or air placebo administered in a rescue trial at 23 hospitals in the United States and 13 hospitals in Canada. Follow-up results were available for 475 of 563 surviving infants who received air placebo (84%) and 482 of 571 infants who received synthetic surfactant (84%). Developmental outcome was equivalent in the two groups. Morbidity was less in the synthetic surfactant group as assessed by the need for medication for chronic lung disease (52 of 475 (11%) for the air placebo group vs 32 of 482 (7%) for the synthetic surfactant group) or respiratory support (10 of 475 (2%) for the air placebo group vs 1 of 482 (< 1%) for the synthetic surfactant group) at 1-year adjusted age. Bayley Scales of Infant Development (mental development Index: 102 for both the air placebo and synthetic surfactant groups; psychomotor development index: 95 for the air placebo group vs 94 for the synthetic surfactant group) and impairment rates (94 of 475 (20%) for the air placebo group vs 86 of 482 (18%) for the synthetic surfactant group) were similar in the two groups. Infants weighing more than 1250 gm who have respiratory distress syndrome have previously been shown to have improved survival rates and lower neonatal morbidity after treatment with synthetic surfactant. These follow-up data confirm that developmental outcome as determined at 12-months adjusted age is at least as good in those receiving synthetic surfactant.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0022-3476
pubmed:author
pubmed:issnType
Print
pubmed:volume
126
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S75-80
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:7745515-Air, pubmed-meshheading:7745515-Child Development, pubmed-meshheading:7745515-Chronic Disease, pubmed-meshheading:7745515-Double-Blind Method, pubmed-meshheading:7745515-Drug Combinations, pubmed-meshheading:7745515-Fatty Alcohols, pubmed-meshheading:7745515-Female, pubmed-meshheading:7745515-Follow-Up Studies, pubmed-meshheading:7745515-Humans, pubmed-meshheading:7745515-Infant, Low Birth Weight, pubmed-meshheading:7745515-Infant, Newborn, pubmed-meshheading:7745515-Lung Diseases, pubmed-meshheading:7745515-Male, pubmed-meshheading:7745515-Nervous System Diseases, pubmed-meshheading:7745515-Phosphorylcholine, pubmed-meshheading:7745515-Polyethylene Glycols, pubmed-meshheading:7745515-Psychomotor Performance, pubmed-meshheading:7745515-Pulmonary Surfactants, pubmed-meshheading:7745515-Respiratory Distress Syndrome, Newborn
pubmed:year
1995
pubmed:articleTitle
Outcome at 1-year adjusted age of 957 infants weighing more than 1250 grams with respiratory distress syndrome randomized to receive synthetic surfactant or air placebo. American and Canadian Exosurf Neonatal Study Groups.
pubmed:affiliation
Department of Pediatrics, Foothills Hospital, Alberta, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial